Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS: Delisting of warrants

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced that NYSE Regulation staff has decided to initiate delisting proceedings for the company's warrants (ticker symbol CLDI WS) from the NYSE American. The warrants, each exercisable for 1/10th of a common stock share at $115.00 per whole share, will be suspended from trading immediately.
The delisting decision is based on Section 1001 of the NYSE American Company Guide, citing the warrants' low trading price as unsuitable for listing. Calidi's common stock (CLDI) will continue to trade on the NYSE American. The company has the right to appeal this decision to the Listings Qualifications Panel. Upon completion of all procedures, including any potential appeal, the NYSE American will apply to the SEC for the official delisting of Calidi's warrants.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
5719 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2619Followers
    107Following
    28KVisitors
    Follow